Los Angeles Capital Management LLC Trims Position in Ironwood Pharmaceuticals, Inc. $IRWD

Los Angeles Capital Management LLC decreased its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 43.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 634,331 shares of the biotechnology company’s stock after selling 495,721 shares during the period. Los Angeles Capital Management LLC owned 0.39% of Ironwood Pharmaceuticals worth $2,138,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IRWD. Integrated Wealth Concepts LLC raised its stake in Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,406 shares during the period. LSV Asset Management purchased a new position in Ironwood Pharmaceuticals during the fourth quarter worth approximately $30,000. Captrust Financial Advisors purchased a new position in Ironwood Pharmaceuticals during the second quarter worth approximately $32,000. Simplify Asset Management Inc. purchased a new position in Ironwood Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, Vise Technologies Inc. purchased a new position in Ironwood Pharmaceuticals during the third quarter worth approximately $39,000.

Insider Activity at Ironwood Pharmaceuticals

In other news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total value of $20,528,940.00. Following the transaction, the director owned 9,188,635 shares of the company’s stock, valued at approximately $28,025,336.75. This trade represents a 42.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 9.30% of the company’s stock.

Ironwood Pharmaceuticals Trading Down 2.1%

Shares of IRWD stock opened at $3.22 on Wednesday. The company’s fifty day simple moving average is $3.82 and its 200-day simple moving average is $3.87. Ironwood Pharmaceuticals, Inc. has a 52 week low of $0.58 and a 52 week high of $5.78. The company has a market cap of $525.05 million, a PE ratio of 5.37 and a beta of 0.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. The business had revenue of $106.51 million during the quarter, compared to analysts’ expectations of $92.11 million. Equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on IRWD shares. Citizens Jmp increased their price target on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group reaffirmed a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.